Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Generated Narrative: Group 179799
version: 3; Last updated: 2023-12-04 20:31:19+0000
Profile: MetaanalysisStudyGroup
Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179799. Revised 2023-12-01. Available at: https://fevir.net/resources/Group/179799. Computable resource at: https://fevir.net/resources/Group/179799.)
Artifact Author: Brian S. Alper:
url: https://fevir.net/resources/Group/179799
identifier: FEvIR Object Identifier/179799
name: MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs
title: MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
description:
Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs (Biegel 2020 data 35/541 vs. 61/521) (Wang 2020 data 15/153 vs. 7/78) (SOLIDARITY data 219/2743 vs. 219/2708)
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
membership: Conceptual
quantity: 3
Code | Value[x] | Exclude | Description |
Member of | EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY) | false | Effect Estimates (Evidence Resources) included in meta-analysis for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs (Biegel 2020) (Wang 2020) (SOLIDARITY) |